NuVasive

SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – AGFS, NUVA, CSII, ANGN

Retrieved on: 
Wednesday, March 15, 2023
Acquisition, Monteverde, Sale, Therapy, NuVasive, NUVA, Testosterone and the cardiovascular system, CSII, Globus Medical, Empire, Abbott Laboratories, Laboratory, Security (finance), Elicio Berriz

Under the terms of the agreement, AGFS shareholders are expected to receive $3.00 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, AGFS shareholders are expected to receive $3.00 in cash per share they own.
  • Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.
  • Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.
  • Under the terms of the agreement, Elicio shareholders are expected to receive new shares of ANGN, with ANGN shareholders expected to own approximately 34.5% of the combined company.

NuVasive to Participate in Upcoming Spine Society Annual Conferences

Retrieved on: 
Tuesday, March 14, 2023
DRS, CNS, Congress of Neurological Surgeons, NUVA, Research, NuVasive, SRS, Czech Institute For International Meetings, Scoliosis Research Society, Congress, American Association of Neurological Surgeons, AANS, Health, SAN, Society, Bookbinding, Pulse, Spine

SAN DIEGO, March 14, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its continued participation at the 2023 Spine Summit held March 16-19 in Miami and the International Meeting on Advanced Spine Techniques (IMAST) held March 22-25 in Dublin.

Key Points: 
  • SAN DIEGO, March 14, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its continued participation at the 2023 Spine Summit held March 16-19 in Miami and the International Meeting on Advanced Spine Techniques (IMAST) held March 22-25 in Dublin.
  • At Spine Summit (booth #228) and IMAST (stand 6), learn about NuVasive's comprehensive, procedurally integrated portfolios—X360, C360, P360 and Complex—enabled by the Pulse platform.
  • Additional activities at each conference include:
    Spine Summit: Special course, Innovations in Spine, will feature product demos of the Pulse platform on March 16 from 1:30 to 4:30 p.m.
  • David Okonkwo and Justin Smith as they review technology-driven strategies and tools to maximize outcomes for challenging spine cases on March 23 from 12:15 to 1:15 p.m. GMT.

NuVasive Celebrates 20-Year Milestone of the XLIF Procedure

Retrieved on: 
Monday, March 13, 2023
Spine, E pluribus unum, Bleeding, NUVA, Rush University Medical Center, NuVasive, Pain, Houston Methodist Hospital, Economics, MIS, Operation Time, Risk management, Pathology, SAN, Complex, X360, Partnership, Houston, Health care, Hospital, Medical imaging, Bookbinding, Pulse

SAN DIEGO, March 13, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the 20-year milestone achievement of its lateral lumbar procedure, extreme lateral interbody fusion (XLIF).

Key Points: 
  • "20 years ago, we set out to make spine surgery more reproducible and improve patient outcomes through the development and introduction of the XLIF procedure," said Ryan Donahoe, chief technology officer at NuVasive.
  • "It's been quite a journey since I started working with NuVasive in 2001, being attracted to the vision of making spine surgery better.
  • "When paired with the enabling technologies within Pulse, XLIF unlocks even more clinical value for both the surgeon and the patient."
  • Building on the legacy of XLIF, the Company has since launched its X360, P360, C360 and Complex procedural portfolios.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, OSH, ANGN, NUVA

Retrieved on: 
Thursday, March 9, 2023
CVS, Advertising, Oak Street, Fraud, Therapy, NuVasive, Globus Medical, Sale, Oak Street Health, NYSE, Security (finance), Elicio Berriz

If you are a Mid Penn shareholder, click here to learn more about your legal rights and options .

Key Points: 
  • If you are a Mid Penn shareholder, click here to learn more about your legal rights and options .
  • If you are an Oak Street shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – NUVA, JNCE, ROCC, TCRR

Retrieved on: 
Wednesday, March 8, 2023
Therapy, Globus Medical, Sale, Empire, NuVasive, Monteverde, ROCC, Primary energy, NUVA, Security (finance), Generic drug, Fenthion

Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.

Key Points: 
  • Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.
  • It is free and there is no cost or obligation to you.
  • Jounce Therapeutics, Inc. (NASDAQ: JNCE ), relating to its proposed merger with Redx Pharma.
  • Under the terms of the agreement, TCRR shareholders are expected to receive 1.5117 shares of Adaptimmune per share they own.

Koa Health appoints Dr. Anna Mandeville as UK Clinical Director and Leslie Norwalk to the Supervisory Board

Retrieved on: 
Wednesday, March 1, 2023
UCL, Biotechnology, Supervisory board, Centers for Medicare & Medicaid Services, Health, Quality management, Mental, Acacia koa, NHS, Neurocrine Biosciences, UK Clinical Pharmacy Association, International Advisory Council, American Mental Health Foundation, WHO, National Health Service, APCO Worldwide, Medicare, University College Hospital, Health Foundation, ModivCare, Hult International Business School, University College London Hospitals NHS Foundation Trust, Psychological Services, Quality, Mental health, Schonfeld Strategic Advisors, NuVasive, Nursing, Pharmaceutical industry

BOSTON, March 1, 2023 /PRNewswire-PRWeb/ -- Koa Health, a leading global provider of digital mental healthcare solutions, today announces that Dr. Anna Mandeville has joined the company's team as UK Clinical Director, and Leslie Norwalk has been appointed to the company's Supervisory Board. Anna will oversee the development of Koa Health's clinical services, and Leslie will serve as an advisor on the US healthcare system.

Key Points: 
  • Dr. Anna Mandeville joins as UK Clinical Director with over 25 years experience in the UK's National Health Service to oversee the development of the company's clinical services, and Leslie Norwalk will serve as a member of the Supervisory Board, advising on the US healthcare system.
  • BOSTON, March 1, 2023 /PRNewswire-PRWeb/ -- Koa Health , a leading global provider of digital mental healthcare solutions, today announces that Dr. Anna Mandeville has joined the company's team as UK Clinical Director, and Leslie Norwalk has been appointed to the company's Supervisory Board.
  • Anna will oversee the development of Koa Health's clinical services, and Leslie will serve as an advisor on the US healthcare system.
  • Consultant Clinical Psychologist Dr. Anna Mandeville joins Koa Health from the NHS, further strengthening the company's clinical expertise
    Dr. Oliver Harrison, CEO, Koa Health, said, "Around the world, people are grappling with the mental health impact of the cost-of-living crisis and political and economic instability (following three years of pandemic).

NuVasive to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, February 27, 2023
Globus Medical, Spine, NUVA, Medtech, SAN, NuVasive, Conference

SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive management will participate in upcoming investor conferences and will be joined by Globus Medical management to discuss the two companies' recent merger announcement and other business topics:

Key Points: 
  • SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that NuVasive management will participate in upcoming investor conferences and will be joined by Globus Medical management to discuss the two companies' recent merger announcement and other business topics:
    Citi 2023 Healthcare Services, MedTech, Tools and HCIT Conference, March 2, 2023 in New York City.
  • Cowen's 43rd Annual Health Care Conference, March 8, 2023 in Boston.
  • Live webcasts of the presentations will be available on the Investor Relations page of the Company's website at www.nuvasive.com .
  • After the live webcasts, replays of the presentations will remain available on the website for 30 days.

ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – NBTB, MPB, CSII, NUVA

Retrieved on: 
Wednesday, February 22, 2023
Testosterone and the cardiovascular system, Monteverde, Acquisition, Empire, NUVA, Laboratory, NBT, NuVasive, Salisbury, Sale, CSII, Globus Medical, Abbott Laboratories, MPB, Security (finance)

Under the terms of the merger, Salisbury shareholders will receive 0.745 shares of NBT per share they own.

Key Points: 
  • Under the terms of the merger, Salisbury shareholders will receive 0.745 shares of NBT per share they own.
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.
  • Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSII, NUVA, ALR

Retrieved on: 
Sunday, February 19, 2023
NuVasive, Sale, Cardiovascular System Dynamics Society, Laboratory, Fraud, Advertising, Globus Medical, Abbott Laboratories, Security (finance)

If you are a Cardiovascular shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Cardiovascular shareholder, click here to learn more about your rights and options .
  • If you are a NuVasive shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – SUMO, CSII, NUVA, FMIA

Retrieved on: 
Saturday, February 18, 2023
Community, Laboratory, Abbott Laboratories, FMIA, NUVA, Francisco Partners, CSII, Globus Medical, Empire, Sale, Monteverde, Testosterone and the cardiovascular system, United Community Bank, SUMO, NuVasive, OTC, Security (finance), United

Under the terms of the agreement, SUMO shareholders are expected to receive $12.05 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, SUMO shareholders are expected to receive $12.05 in cash per share they own.
  • Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.
  • Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.
  • Under the terms of the agreement, FMIA shareholders are expected to receive 10.2685 shares of United per share they own.